Viromed Medical AG (ISIN: DE000A3MQR65), a medical technology company specializing in cold plasma technology, today provided a strategic update on its operational orientation. The company reaffirms its commitment to sustainable, technology-driven growth in the international MedTech market, focusing on innovative medical devices and translational research for severe respiratory diseases, particularly ventilator-associated pneumonia (VAP).
Over the past two years, Viromed has developed two novel cold plasma medical devices: ViroCAP® for medical wound healing and PulmoPlas®, a globally unique cold plasma system for pneumology and respiratory tract infections. PulmoPlas® is highlighted as the next-generation technological platform, forming the basis for future scaling across multiple medical indication areas.
In the research domain, Viromed has established a high-performance scientific consortium comprising Hannover Medical School (MHH), the Helmholtz Centre for Infection Research (HZI) in Braunschweig, and the Leibniz Institute in Jena. This network brings together top-level expertise in infectiology, pneumology, and translational research. The comprehensive publication of results by MHH and HZI is expected at the end of January 2026.
For technological development, Viromed works closely with Relyon Plasma, a subsidiary of TDK. International partnerships in Europe, Korea, and Turkey support future market entry and underscore the global relevance of the technology. As a result of the strategic focus on research, development, and international market structures, longer innovation cycles arise. Viromed deliberately refrains from communicating short-term operational interim updates, reporting only substantial and relevant milestones.
Viromed’s corporate strategy is geared toward long-term value generation, with research and development programs aligned with medical benefit, clinical relevance, and sustainable market potential. The company is recognized as a pioneer in pneumological research and plasma technology, with the potential to significantly shape future therapeutic approaches for severe respiratory infections. According to its own assessment, Viromed will play a significant role in the global fight against pathogenic germs, particularly with PulmoPlas®.
Additionally, Viromed has successfully overcome new, stringent regulatory hurdles for the approval of ViroCAP® over the past 18 months. Market acceptance and demand for ViroCAP® are already very high. More information can be found at www.viromed-medical-ag.de.
